Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection. Supplementary Information The online version contains supplementary material available at 10.1007/s15010-021-01657-y.
【저자키워드】 COVID-19, SARS-CoV2, bamlanivimab, Casirivimab, Imdevimab, Monoclonal spike antibodies, 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, Mortality, antibody, cross-sectional, SARS-COV-2 infection, monoclonal antibody, nosocomial, Infection, outcome, monoclonal antibodies, bamlanivimab, Population, Disease progression, Retrospective study, Casirivimab, Imdevimab, Patient, asymptomatic patients, asymptomatic patient, monoclonal, SARS-CoV-2 spike, Coronavirus-2, severe disease, high risk, acute respiratory syndrome, supplementary material, acute respiratory syndrome coronavirus, significant decrease, characterized, 【제목키워드】 therapy, hospital, monoclonal antibody, nosocomial, Germany, Patient,